Key technological innovations have converged to make community-based campaigns to provide Active Case Finding (ACF) and TB Preventive Treatment (TPT) increasingly feasible over the past 5 years:
- Novel mobile x-ray with artificial intelligence = human, can screen masses.
- GeneXpert with results in ~2 hours, more accurate than microscopy, faster than culture
- Novel regimens with shortened duration; low drug burden and cost
- Venue based screening (VBS), future active case finding
Therefore, the overall goal of the study is to evaluate the comparative effectiveness and implementation of this combination intervention under two different approaches; a clinic-based strategy and a community “hotspot-focused” approach.
People served
Adults 15 years and above, plus their TB contacts 5 years and above
Funder
United States National Institutes of Health (NIH)-funded cluster randomized trial (5R01HL138728-06; PIs: Kendall, Dowdy, Katamba)